Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19.

ABSTRACT: Introduction. The ID NOW is FDA approved for the detection of SARS-CoV-2 in symptomatic individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 h of specimen collection.Gap statement. Clinical data on the performance of the ID NOW are limited, with many studies varying in their study design and/or having small sample size.Aim. In this study we aimed to determine the clinical performance of the ID NOW compared to conventional RT-PCR testing.Methodology. Adults with COVID-19 in the community or hospital were recruited into the study. Paired throat swabs were collected, with one throat swab transported immediately in an empty sterile tube to the laboratory for ID NOW testing, and the other transported in universal transport media and tested by an in-house SARS-CoV

SUBMITTER: Stokes W 

PROVIDER: S-EPMC8493423 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature